Collectively, our findings highlight IGFBP-5 as a potential prognostic marker, demonstrate the tumour-inhibitory effect of ERβ silencing, and identify GPER1 as a promising therapeutic target linking estrogen signalling, lipid metabolism, and CRC progression. The gene discussed is GPER1; the disease is colorectal carcinoma.